This study is looking at how well a new drug called **olorofim** works against a lung infection caused by a fungus called **Aspergillus**. **Aspergillus** can cause serious illness, especially in people with weak immune systems. The study will compare olorofim to a drug called **AmBisome®**, which is already used to treat this infection. Some patients need new treatments because the fungus can resist drugs like **azoles** and **amphotericin B**.

Olorofim is promising because it can be taken by mouth and works differently than other drugs, possibly with fewer side effects. The study will check if it's safe and works as well as or better than AmBisome®. To join, you must be over 18, weigh more than 30 kg (about 66 pounds), and have a confirmed Aspergillus infection. You cannot join if you're pregnant, have certain other infections, or are allergic to the study drug.

• Study involves comparing olorofim and AmBisome® treatments.
• Participants must be adults with confirmed Aspergillus infection.
• Excludes pregnant women and those with certain health conditions.